Monitor for any strategic shifts in board committee focus given Dr. Brailer's health-tech and managed care background, but this appointment alone is routine and unlikely to drive near-term stock movement.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Oct 29 $42.09entry
- T+1 · 6d ago −3.30%α −2.82% · $40.70
- T+5 · due 12h ago Pending
- T+5 · todayOpen
- T+20 · in 22d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Teva elected Dr. David J. Brailer to its Board of Directors, effective November 3, 2026, until the 2027 annual meeting. Dr. Brailer is an independent director with a background in health-tech and managed care, and will serve on the Human Resources and Compensation and Compliance Committees. This is a routine board appointment with no material financial impact.
Key Facts
- Dr. David J. Brailer elected to Teva's Board effective November 3, 2026
- Dr. Brailer qualifies as an independent director under NYSE listing rules
- He will serve on the Human Resources and Compensation and Compliance Committees
- Compensation is the same as other non-executive directors, as described in the March 31, 2026 proxy statement
- No arrangements or understandings with any other person regarding his election
- No material interest in any related party transaction and no family relationships with any director or executive officer
Financial Impact
No financial impact; standard director compensation as disclosed in prior proxy
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-438019 |
| Document: 0001193125-26-438019-index-headers.html | 0001193125-26-438019 |
| Document: 0001193125-26-438019-index.html | 0001193125-26-438019 |
| Document: 0001193125-26-438019.txt | 0001193125-26-438019 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Nov 5, 2026 today | 144 | $41.89 | awaiting T+20 | awaiting T+20 | $41.78 (−0.26%) |
Nov 4, 2026 1d ago | 144 | $41.85 | awaiting T+20 | awaiting T+20 | $41.78 (−0.17%) |
Nov 3, 2026 2d ago | 8-K | No price | awaiting T+20 | awaiting T+20 | No price |
Nov 3, 2026 2d ago | Press Release | $41.91 | awaiting T+20 | awaiting T+20 | $41.78 (−0.31%) |
Nov 3, 2026 2d ago | Press Release | $41.91 | awaiting T+20 | awaiting T+20 | $41.78 (−0.31%) |
Nov 2, 2026 3d ago | Press Release | $40.70 | awaiting T+20 | awaiting T+20 | $41.78 (−2.65%) |
Nov 2, 2026 3d ago | SC 13G/A | $40.70 | awaiting T+20 | awaiting T+20 | $41.78 (+2.65%) |
Oct 29, 2026 7d ago | 8-K | $42.09 | awaiting T+20 | awaiting T+20 | $41.78 (−0.74%) |
Oct 27, 2026 9d ago | Press Release | $40.39 | awaiting T+20 | awaiting T+20 | $41.78 (+3.44%) |
Oct 15, 2026 21d ago | Institutional Cluster | $41.11 | awaiting T+20 | awaiting T+20 | $41.78 (−1.63%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers